Resources Repository
-
ArticlePublication 2017Cost-Effectiveness of Intensive versus Standard Blood-Pressure Control
Based on data from the Systolic Blood Pressure Intervention Trial (SPRINT), the authors of this …
Based on data from the Systolic Blood Pressure Intervention Trial (SPRINT), the authors of this article compared the cost-effectiveness of intensive versus standard control in adults at high risk for cardiovascular disease who received intensive systolic blood-pressure control. A microsimulation model was used to project lifetime costs of treatment and monitoring, cardiovascular disease events and subsequent treatment costs, treatment-related risks of serious adverse events and subsequent costs, and quality-adjusted life-years (QALYs) for the two strategies.…
Microsimulation | Health/Medicine | North America | Chronic Disease/Risk | Health Outcomes | Cost-Effectiveness Analysis -
ArticlePublication 2016Cost-Effectiveness of Hypertension Treatment According to 2014 Guidelines
This article compared the cost-effectiveness of hypertension treatment in non-Hispanic blacks and non-Hispanic whites according …
This article compared the cost-effectiveness of hypertension treatment in non-Hispanic blacks and non-Hispanic whites according to 2014 US hypertension treatment guidelines. The cardiovascular disease (CVD) policy model was used to simulate CVD events, quality-adjusted life years (QALYs), and treatment costs in 35- to 74-year-old adults with untreated hypertension. CVD incidence, mortality, and risk factor levels were obtained from cohort studies, hospital registries, vital statistics, and national surveys. The authors assumed a willingness-to-pay for health of…
Microsimulation | Health/Medicine | North America | Chronic Disease/Risk | Cost-Effectiveness Analysis -
ArticlePublication 2016Cost-Effectiveness of Intensive Blood Pressure Management
This article aimed to evaluate the cost-effectiveness of intensive blood pressure management compared with standard …
This article aimed to evaluate the cost-effectiveness of intensive blood pressure management compared with standard management among 68-year-old high-risk adults with hypertension but not diabetes. A Markov cohort model was developed to estimate lifetime costs and quality-adjusted life-years (QALYs) discounted at 3% annually. The Systolic Blood Pressure Intervention Trial (SPRINT) was used to estimate treatment effects and adverse event rates. The authors used Centers for Disease Control and Prevention Life Tables to project age- and…
State-Transition | Health/Medicine | North America | Chronic Disease/Risk | Cost-Effectiveness Analysis -
ArticlePublication 2016Cost-Effectiveness of Blood Pressure Treatment Guidelines in Adults 35-74
In this article the authors used the CVD Policy Model to compare the cost-effectiveness of …
In this article the authors used the CVD Policy Model to compare the cost-effectiveness of conservative versus intensive blood pressure treatment guidelines in adult hypertensive patients aged 35 to 74 years. Outcomes included in the study were CVD events, treatment costs, quality-adjusted life years, and drug and monitoring costs projected over the years 2016 to 2026. The effectiveness and costs of hypertension were calculated for treatment according to the 2003 Joint National Committee (JNC)-7 or…
Microsimulation | Health/Medicine | North America | Chronic Disease/Risk | Cost-Effectiveness Analysis | Clinical Care -
ArticlePublication 2016Prevention of Hepatitis C by Screening and Treatment in U.S. Prisons
This study assesses the health and economic impact of hepatitis C virus (HCV) screening and …
This study assesses the health and economic impact of hepatitis C virus (HCV) screening and treatment in U.S. prisons on the broader HCV epidemic. Employing an agent-based microsimulation model of HCV transmission and disease progression, data from published literature inform the analysis. The target populations include individuals in U.S. prisons and the general community over a 30-year timeframe, adopting a societal perspective. Interventions encompass risk-based and universal opt-out HCV screening in prisons, followed by treatment…
Microsimulation | Health/Medicine | North America | Chronic Disease/Risk | Cost-Effectiveness Analysis | Infectious Diseases -
ReviewPublication 2015Economic Evaluation of Diet and Physical Activity to Prevent Type 2 Diabetes: Systematic Review
Studies indicate that combined diet and physical activity promotion programs can prevent type 2 diabetes …
Studies indicate that combined diet and physical activity promotion programs can prevent type 2 diabetes among persons at increased risk. This paper systematically evaluates the evidence on cost, cost-effectiveness, and cost–benefit estimates of diet and physical activity promotion programs. English-language studies from high-income countries that provided data on cost, cost-effectiveness, or cost–benefit ratios of diet and physical activity promotion programs with at least 2 sessions over at least 3 months delivered to persons at increased risk…
Evidence Synthesis | Health/Medicine | North America | Chronic Disease/Risk | Cost-Effectiveness Analysis | Child/Nutrition | Social Determinants | Health Systems | Food/Agriculture | Europe | Asia & Pacific -
ArticlePublication 2015Cost-Effectiveness & Budget Impact of Hepatitis C Virus Treatment with Sofosbuvir & Ledipasvir in the U.S.
This study evaluates the cost-effectiveness and budget impact of sofosbuvir and ledipasvir for treating chronic …
This study evaluates the cost-effectiveness and budget impact of sofosbuvir and ledipasvir for treating chronic hepatitis C virus (HCV) infection compared to the old standard of care (oSOC). Using a microsimulation model based on HCV natural history, data from published literature, and a third-party payer perspective, the analysis considers treatment-naive and treatment-experienced HCV populations in the United States over a lifetime horizon. Sofosbuvir-based therapies are found to add 0.56 quality-adjusted life-years (QALYs) relative to oSOC,…
Microsimulation | Health/Medicine | North America | Chronic Disease/Risk | Cost-Effectiveness Analysis | Infectious Diseases -
ArticlePublication 2014Cost-Effectiveness of Second-Generation Antipsychotics for the Treatment of Schizophrenia
This article, published in Value in Health, describes a Markov model that compares the cost-effectiveness …
This article, published in Value in Health, describes a Markov model that compares the cost-effectiveness of alternate sequences of treatment strategies using second-generation antipsychotics (SGAs) for patients with schizophrenia. First-line treatments include one of the four SGAs: olanzapine (OLZ), risperidone (RSP), quetiapine (QTP), and ziprasidone (ZSD). Patients are able switch to another of these antipsychotics as second-line therapy, and only clozapine (CLZ) is allowed as third-line treatment. Model input parameters were obtained from the Clinical…
State-Transition | Health/Medicine | North America | Mental Health | Cost-Effectiveness Analysis -
ArticlePublication 2012Modeling the Risks and Benefits of Depression Treatment for Children and Young Adults
This article, published in Value in Health, presents a discrete event simulation model to quantify …
This article, published in Value in Health, presents a discrete event simulation model to quantify the trade-offs with respect to clinical benefits and the risk of fatal and non-fatal suicidal behavior of alternative treatment strategies for a U.S. pediatric population with major depressive disorder. The authors evaluate treatment strategies including: selective serotonin reuptake inhibitors (SSRIs), cognitive behavioral therapy (CBT), and a combination of both. The results show that the use of SSRIs is associated with…
Microsimulation | Health/Medicine | North America | Mental Health | Health Outcomes | Technology Assessment